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Background: Acute lung injury (ALI) and its most severe form acute respiratory distress syndrome (ARDS) have
been the leading cause of morbidity and mortality in intensive care units (ICU). Currently, there is no effective
pharmacological treatment for acute lung injury. Curcumin, extracted from turmeric, exhibits broad anti-inflammatory
properties through down-regulating inflammatory cytokines. However, the instability of curcumin limits its clinical
application.
Methods: A series of new curcumin analogs were synthesized and screened for their inhibitory effects on the
production of TNF-α and IL-6 in mouse peritoneal macrophages by ELISA. The evaluation of stability and mechanism of
active compounds was determined using UV-assay and Western Blot, respectively. In vivo, SD rats were pretreatment
with c26 for seven days and then intratracheally injected with LPS to induce ALI. Pulmonary edema, protein
concentration in BALF, injury of lung tissue, inflammatory cytokines in serum and BALF, inflammatory cell
infiltration, inflammatory cytokines mRNA expression, and MAPKs phosphorylation were analyzed. We also
measured the inflammatory gene expression in human pulmonary epithelial cells.
Results: In the study, we synthesized 30 curcumin analogs. The bioscreeening assay showed that most compounds
inhibited LPS-induced production of TNF-α and IL-6. The active compounds, a17, a18, c9 and c26, exhibited their
anti-inflammatory activity in a dose-dependent manner and exhibited greater stability than curcumin in vitro.
Furthermore, the active compound c26 dose-dependently inhibited ERK phosphorylation. In vivo, LPS significantly
increased protein concentration and number of inflammatory cells in BALF, pulmonary edema, pathological
changes of lung tissue, inflammatory cytokines in serum and BALF, macrophage infiltration, inflammatory gene
expression, and MAPKs phosphorylation. However, pretreatment with c26 attenuated the LPS induced increase
through ERK pathway in vivo. Meanwhile, compound c26 reduced the LPS-induced inflammatory gene expression
in human pulmonary epithelial cells.
Conclusions: These results suggest that the novel curcumin analog c26 has remarkable protective effects on
LPS-induced ALI in rat. These effects may be related to its ability to suppress production of inflammatory cytokines
through ERK pathway. Compound c26, with improved chemical stability and bioactivity, may have the potential to be
further developed into an anti-inflammatory candidate for the prevention and treatment of ALI.
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Acute lung injury (ALI) is defined as acute inflammatory
lung injuries associated with histopathological changes in-
cluding neutrophilic alveolar infiltrates, impaired alveolar
fluid clearance, fibrin deposition and lung edema. Despite
advances in therapies, the outcomes of ALI in critically ill
patients remain dismal with a morbidity and mortality rate
around 40% [1-3]. With improved understanding of the
pathogenesis of ALI, accumulating evidence shows that
the release of pro-inflammatory cytokines play a critical
role in inflammation-induced lung injury. Previous reports
indicated that tumor necrosis factor (TNF)α, interleukin
(IL)6, IL-1β, and IL8 are the key inflammatory mediators
involved in the progression of ALI [4-6].
Numerous pharmacological agents were investigated in
an effort to attenuate the release of these pro-inflammatory
cytokines involved in ALI. In pre-clinical experiments,
these anti-inflammatory agents have demonstrated potent
inhibitory effects on the release of inflammatory mediators
and protective effects on ALI [7-10]. However, several
pharmacological therapeutic trials failed to demonstrate
any benefit in patients with ALI [11,12]. The failure of
prior clinical trials of several pharmacological agents
may be partly due to the delay of therapy which oc-
curred several days after the onset of ALI. Therefore,
pharmacological therapies for prevention or early inter-
vention of ALI have emerged as a new paradigm [3]. Some
of the most promising therapeutic agents for early treat-
ment of ALI include aspirin, statins, beta-2 adrenergic ag-
onists, corticosteroids, vitamin D, and butyrate [3,13-15].
Curcumin, a natural product isolated from turmeric, has
been found to have broad anti-inflammatory activities both
in vitro and in vivo. However, the poor solubility and chem-
ical instability of curcumin, under physiological conditions,
limit its bioavailability and clinical efficacy [16-18]. Curcu-
min analogs have been designed to improve bioavailability
and bioactivity. Among them, mono-carbonyl analogs of
curcumin (MACs) demonstrate excellent chemical stability
and pharmacokinetic profiles [19-21]. We previously synthe-
sized and identified a mono-carbonyl analog of cucurmin
(C66), which demonstrated excellent chemical stability and
potent anti-inflammatory effects both in vivo and in vitro
[22,23]. Recent studies indicate that curcumin has potential
protective effects for ALI [24-26]. However, there is no re-
port on the effects of curcumin analogs on lipopolysacchar-
ide (LPS)-induced ALI. We considered that the investigation
of the effects of novel curcumin analogs with improved
chemical stability may discover novel anti-inflammatory
candidate agents for the prevention or treatment of ALI.
Materials and methods
Animals and reagents
Male ICR mice (6 wk, 18-20 g) and Sprague–Dawley (SD)
rats (6 wk, 180-200 g) were obtained from ShanghaiSLAC Laboratory Animal Center, CAS (SLACCAS). Mice
were housed under specific pathogen-free conditions with
a 12-hour/12-hour light–dark cycle and maintained on
a normal diet at Wenzhou Medical University Animal
Center. All mice and in vivo experiments were performed
in accordance with procedures approved by Wenzhou
Medical University Animal Policy and Welfare Committee
(Approval Documents: 2013/APWC/0361).
LPS was purchased from Sigma (St. Louis, MO). Enzyme-
linked immunosorbent assay (ELISA) kits of TNF-α and
IL-6 were obtained from eBioscience, Inc. (San Diego, CA,
USA). Extracellular signal-regulated kinase (ERK), p-ERK
and CD68 antibodies were purchased from Santa Cruz
Biotechnology, Inc., (Santa Cruz, CA, USA). Antibodies
of p-P38, P38, p-Jun N-terminal kinase (JNK), and JNK
were obtained from Cell Signaling Technology, Inc.,
(Danvers, MA, USA).Harvest and culture of mouse primary peritoneal
macrophages (MPMs)
ICR mice were stimulated by intraperitoneal injection of
6% thioglycolate broth (0.3 g beef extract, 1 g tryptone,
0.5 g NaCl and 6 g starch dissolved in 100 mL H2O,
1.5 mL/mouse) for 3 days before sacrificed for MPMs
harvest. MPMs were then centrifuged and suspended
in RPMI-1640 medium (Gibco/BRL life Technologies,
Eggenstein, Germany) supplemented with 10% FBS and
1% penicillin/streptomycin. The cells were incubated over-
night at 37°C in a 5% CO2-humidified air.Detection of TNF-α and IL-6 expression by ELISA
The MPMs harvested were pre-treated with curcumin
(10 μM), compounds (10 μM), or DMSO (control) for
30 minutes, which was followed by the treatment of
0.5 μg/mL LPS. After treatment, the cells were incubated
for 24 hours. The media were collected to measure the
amount of TNF-α and IL-6 through the use of ELISA kit
(eBioScience, San Diego, CA) according to manufacturer’s
protocol. The total protein concentrations in viable cell
pellets were measured. The amounts of TNF-α and IL-6
were normalized to the total proteins in cells.Chemical stability analysis of curcumin analogs by UV
absorbance spectroscopy
Curcumin or the active compounds were dissolved in
DMSO (1 mM) and diluted with PBS (pH 7.4) to 20 μM.
The absorbance spectra were taken from 250 to 600 nm
at 25°C on SpectraMax® M5 (Molecular Devices LLC,
Sunnyvale, CA, USA). Absorbance spectral readings were
recorded for over a time span of 25 minutes at 5 minute
intervals.
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The macrophages harvested from mice were pre-
treated with the active compounds or DMSO (control)
for 30 minutes and then incubated with 0.5 μg/mL LPS
for 20 minutes. After treatment, protein samples were col-
lected, separated by SDS-PAGE, and transferred to PVDF
membranes. Membranes were incubated with a blocking
solution of 5% non-fat milk for 1.5 h at room temperature.
Proteins on membranes were then separately probed
with the primary antibodies overnight. Protein samples
were further incubated with horseradish peroxidase-
conjugated (HRP) secondary antibodies for 1 h, and vi-
sualized using enhanced chemiluminescence reagents
(Bio-Rad Laboratories).Animal models of ALI
SD rats were randomly placed into three groups (n = 6,
each group). The rats were anesthetized and the tracheas
were surgically exposed. Group 1 (CON group) received
an intratracheal injection of saline. Group 2 (LPS group)
received a drop-wise intratracheal injection of LPS
(5 mg/kg, 50 μL), Group 3 (CUR + LPS group) and
Group 4 (c26 + LPS group) received an intra-gastric ad-
ministration of compound c26 (20 mg/kg/day) daily for
seven days prior to the administration of LPS (50 μL,
5 mg/kg). Six hours after LPS administration, all animals
were anesthetized by chloral hydrate and sacrificed.
Broncho-alveolar lavage fluids (BALF) were collected for
determination of total protein concentration and inflam-
matory cell infiltration. The lobes of the right lung were
harvested for the study of curcumin and c26 on LPS in-
duced lung injury analysis.BALF
Thoracotomy and ligation of the left lung were per-
formed. The left lung was infused three times with 1 mL
phosphate buffered saline (PBS) in order to obtain BALF
as previously described [27]. The collected BALF was cen-
trifuged for 10 minutes at 1,000 rpm. Cell-free supernatant
was used for measurement of target protein cytokines.
The cell pellets obtained from BALF were washed and
re-suspended in 50 μL PBS for cell counting with a
Hemocytometer.Lung wet/dry weight ratio
The right upper lobe of lung was excised. After removal
of the excessive water on the tissue surface, the wet
weight was recorded. The sample was then dried at 60°C
for 48 h until no weight change to record the dry weight.
The wet weight/dry weight ratio (W/D) was calculated
and used as an index of lung edema.Pulmonary histopathology and immunohistochemistry
analysis
The right lower lobe of lung was excised and fixed
with 4% formalin. The lung tissues were embedded
with paraffin, sliced to 5 μm sections, and stained with
hematoxylin and eosin (HE). Rat lung histopathology
images were acquired using a microscope (Nikon Model
Eclipse 80i, Nikon, Tokyo, Japan). The immunohistochem-
istry analysis was performed following the anti-CD68 anti-
body staining protocol.
Histological analysis
The lung injury was evaluated by Lung injury scoresas
described previously [28]. In brief, no injury = score of 0;
injury in 25% of the field = score of 1; injury in 50% of
the field = score of 2; injury in 75% of the field = score of
3; and injury through out the field = score of 4. Ten ran-
dom microscopic fields from each slide were analyzed.
The average score of the 10 slides was used to assess the
severity of lung injury.
Real-time PCR analysis for mRNA expressions of TNF-α,
IL-6, IL-1β and COX-2
Total RNA was isolated from Beas-2B cells or lung tissue
of rats with ALI using Trizol, then reversely transcribed to
cDNA using M-MLV according to guidelines of the manu-
facturer. Gene specific primers used for TNF-α, IL-6,
IL-1β, COX-2 and β-actin are listed in Additional file 1:
Table S1.
Statistical analysis
Data collected from experiments were analyzed using
Graphpad prism 5.0 software. Values were expressed as
mean ± SEM. One way ANOVA test was employed to
analyze the differences between sets of data. A p-value
of < 0.05 was considered as statistically significant and
denoted as*. In vitro experiments were performed with
n ≥ 3 independent repeats. In vivo experiments were
performed with n ≥ 5 rats in each group.
Results
Chemistry
In the present study, curcumin analogs were obtained
from the Claisen–Schmidt condensation of substituted
3-phenyl-ketone and various aromatic aldehydes. The
synthetic roots were listed in Scheme 1 and Scheme 2
and the chemical structures of these analogs were shown
in Figure 1. Reaction progress was monitored by thin layer
chromatography (TLC) and the structures of compounds
were confirmed by ESI-MS and 1H-NMR. The detailed
synthetic routes, synthetic yields, melting points, 1H-
NMR, and ESI-MS analysis of novel and unpublished


















3a: n= 2, R1= -CF3
3b: n= 3, R1= -CF3
4a: n= 2, R1= -NO2





Reagents and conditions: (i) 4-Methylbenzenesulfonic acid, toluene, reflux, 4h, 60-65%; (ii) EtOH, 
reflux, 5h,  saturate HCl, 20-30%; (iii) Various aromatic aldehydes, HCl gas, EtOH, rt, 10h, 20-80% 
or 20% NaOH, EtOH, rt, 10h, 20-80% .
Scheme 1 The synthetic pathway of curcumin analogs.
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expression of cytokines TNF-α and IL-6
As shown in Figure 2A and B, the expressions of TNF-α
and IL-6 were significantly increased in mice macro-
phages with the treatment of LPS. Some of the analogs
showed stronger activity than the leading compound, cur-
cumin, for inhibiting the production of TNF-α and IL-6.
Pretreatment with compound a9, a10, a17, a18, c9 or
c26 (10 μM) for 30 minutes significantly suppressed the
release of IL-6 with an inhibition rate of above 80%
(Figure 2A). In addition, compounds a2, a9, a10, a13,
a17, a18, c9 or c26 (10 μM) markedly attenuated the
expression of TNF-α (Figure 2B). Compounds a17, a18,
c9 and c26 efficiently inhibited the expression of both
TNF-α and IL-6. The most potent compounds, c9 and
c26, inhibited virtually all releases of TNF-α and IL-6 in
MPMs stimulated by LPS. The results from Figure 2
show that compounds, substituted by –NO2 on R1, ex-
hibited stronger inhibitory activity than –CF3 on R1.
Compared with cyclopentanone as the connecting link,
cyclohexanone contributes to potent anti-inflammatory







Reagents and conditions: (i) Acetone, 20%
NaOH powder, rt, 5h, 70-80% 
Scheme 2 The synthetic pathway of curcumin analogs c9 and c26.R2 containing methoxyl and/or hydroxyl group on the
phenyl ring showed better anti-inflammatory activities
than their correspondence with the electron-withdrawing
group.
The effects of a17, a18, c9 and c26 on the expression of
IL-6 and TNF-α
The most active compounds, a17, a18, c9 and c26, were
further evaluated for their effects on the production of
IL-6 and TNF-α in a dose-dependent manner. First, we
evaluated the cytotoxicity of these active compounds using
the MTT assay. The results shown in Additional file 3:
Figure S1 and show no cytotoxicity. Then MPMs were
pretreated with a17, a18, c9 or c26 in an escalating
doses (1, 5, 10 μM), or DMSO (control) for 30 minutes,
followed by the treatment of 0.5 μg/mL LPS. As shown
in Figure 3, compounds a17, a18, c9, and c26 significantly
inhibited LPS-induced TNF-α and IL-6 release in a dose
dependent manner. All four active compounds showed
better inhibitory activity than curcumin even at 5 μM.
The most potent compound, c26 (5 μM), demonstrated





 NaOH, rt, 4h, 40-60%; (ii) Dixane,













































































































































Figure 1 The structures of synthesized curcumin analogs.
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validate that these compounds possess significant anti-
inflammatory activity.
Chemical stability analysis of bioactive compounds a17,
a18, c9 and c26
Previous report showed that 90% of curcumin rapidly
decomposes in the physiological buffer solution (pH 7.4)
which limits its bioavailability in clinical application [29].
To examine the chemical stability of these bioactive com-
pounds, UV absorption spectra of bioactive compounds
a17, a18, c9, and c26 in PBS (5% DMSO and pH 7.4)
were measured at different time points (0–25 min).
Figure 4 shows that no significant changes in absorb-
ance were observed for these bioactive compounds over
the time. As a comparison, the UV peak absorbance of
curcumin decreased significantly within 25 minutes as
a result of chemical degradation. Meanwhile,we used
the UV assay to detect the stability of these compounds
after a longer period of incubation in PBS at 37°C (Data is
shown in Additional file 3: Figure S2). The UV peak ab-
sorbance was disappeared after an incubation of 30 minutes,while the active compounds showed no obvious changes
within 1 hour incubation. The results indicate that these
novel curcumin analogs are chemically stable in the
simulated physiological buffer solution (PBS, pH 7.4) as
compared with curcumin.
Effect of c26 on the phosphorylation of ERK, JNK, and
p38 in MAPK pathways
Previous studies have shown that multiple signaling path-
ways are involved in stimulating the releases of inflamma-
tory cytokines. One of the critical signaling pathways is
the Mitogen-activated protein kinase (MAPKs) pathway,
which is comprised by ERK, c-Jun amino-terminal kinases
(JNK), and p38. To investigate the possible mechanism by
which the representative compound c26 exerts its anti-
inflammatory activity in vitro, we measured the effects of
c26 on phosphorylation of ERK, JNK, and p38. Figure 5A
shows that the phosphorylation level of ERK (p-ERK),
JNK (p-JNK), and p38 (p-p38) markedly increased
after LPS treatment. Pre-treatment of c26 (10 μM) for
30 minutes significantly inhibited the phosphorylation

































































































































































































Figure 2 Production of LPS-induced inflammatory cytokines in mouse peritoneal macrophages after treatment with curcumin derivatives.
Macrophages were treated with vehicle or 10 μM curcumin derivatives or 10 μM curcumin for 30 minutes, and the LPS (0.5 μg/mL) was added to
incubate for further 24 hours. The culture media was collected and the inflammatory cytokines, IL-6 (A) and TNF-α (B), in media were detected by ELISA
and normalized by total protein concentration. The results were presented as the percent of LPS control. Each bar represents mean ± SEM of three
independent experiments. Statistical significance relative to LPS group was indicated, *p < 0.05, **p < 0.01.
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strates that the active compound c26 (2.5 20 μM) down-
regulated the phosphorylation of ERK in a dose dependent
manner.
The effects of c26 on pulmonary histopathological changes
of lungs in rats with ALI
Gram-negative bacterial pneumonia and sepsis are major
causes of clinical ALI. LPS, a component of the cell walls
of gram-negative bacteria, was used to stimulate ALI in
rat models in vivo. Figure 6A shows significant elevations
of protein concentrations in BALF after LPS administra-
tion. The increased levels of protein concentrations in
BALF were significantly reduced by administration of
curcumin (CUR + LPS) or c26 (c26 + LPS). Lung wet/dryweight ratio is an index of lung edema. Figure 6B illus-
trates that LPS administration stimulated the increase of
lung wet/dry weight ratio as compared with the control
group. Pretreatment of c26 (c26 + LPS) reduced lung
wet/dry weight ratio, while pretreatment with curcumin
(CUR + LPS) showed no obvious effect. Figure 6C shows
the effects of compound c26 on the histopathological
features of rat lungs with ALI. The control group shows
normal structure of rat lung tissues. In the LPS group,
remarkable alveolar wall thickness, hemorrhage, alveolar
collapse, and inflammatory infiltration were observed in
the lungs six hours after LPS administration (Figure 6C,
middle panel). As a comparison, the CUR + LPS group
and c26 + LPS group show normal lung structure and
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Figure 3 Active compounds inhibited LPS-induced inflammatory cytokines in a dose-dependent manner. Macrophages were treated with
vehicle, 10 μM curcumin or (1, 5, 10 μM) active compounds for 30 minutes, and the LPS (0.5 μg/mL) was added to incubate for further 24 hours.
The culture media was collected and the inflammatory cytokines IL-6 (A) and TNF-α (B) in media were detected by ELISA and normalized by total
protein concentration. The results were presented as the percent of LPS control. Each bar represents mean ± SEM of three independent experiments.
Statistical significance relative to LPS group was indicated, *p < 0.05, **p < 0.01.
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indicate that c26 administration efficiently attenuated
hemorrhage, alveolar collapse, and lung edema in rats
with ALI.
Effect of c26 on inflammatory cell infiltrations in rat lungs
with ALI
After onset of ALI, inflammatory cell infiltration in lung
tissues and alveoli could further facilitate the inflamma-
tory process associated with ALI. We examined the cell
number in BALF, as shown in Figures 7A and 6B the
neutrophil and monocyte numbers were markedly in-
creased after LPS instillation. The CUR and c26 reduced
the LPS-induced inflammatory cells increase. To examine
the effect of c26 on macrophage infiltration in harvested
rat lung tissue, we performed an immunohistochemical
analysis with CD68 antibody. Rat lung tissue from thecontrol group showed nomacrophage infiltration (Figure 7C).
In the LPS group, significant macrophage infiltration in rat
lung tissue was observed. In the CUR+LPS group and the
c26+LPS group, very minor macrophage filtration in lung
was detected when compared to those in the LPS group
(Figure 7C). Pro-inflammatory cytokines, including
TNF-α, and IL-6, are major mediators involved in re-
cruitment of neutrophils into the lungs in LPS-induced
ALI. After LPS treatment, the concentration of TNF-α
was increased both in serum and BALF. The response
was significantly reduced by pre-treatment with curcu-
min or c26. Taken together, both curcumin and c26
show obvious anti-inflammatory effects in vivo.
The potential anti-inflammatory mechanism of c26 in vivo
Next, we measured whether pretreatment with the ad-
ministration of c26 could reduce the elevated mRNA
c26


















































































Figure 4 UV-visible absorption spectra of curcumin, a17, a18, c9, and c26 in phosphate buffer (pH 7.4), containing 5% DMSO. The compounds
stability was described by the curve which is consisted of absorbance at various optical density (250–600 nm) and intervals (0, 5, 10, 15, 20, 25 min).
(A) curcumin; (B) a17; (C) a18; (D) c9; (E) c26.
Zhang et al. Respiratory Research  (2015) 16:43 Page 8 of 13expression levels of inflammatory cytokines in rat lung
tissue. Significant increases in mRNA levels were observed
for inflammatory mediators TNF-α (Figure 8A), IL-6
(Figure 8B), IL-1β (Figure 8C), and COX-2 (Figure 8D)
after LPS administration. In contrast, administration of













Figure 5 Compound c26 inhibited ERK phosphorylation. (A) Macroph
with LPS (0.5 μg/mL) for an additional 20 minutes. Cells were harvested a
p-JNK, JNK, p-P38, and P38 was determined by western blot, respectively. (B)
Representative blots of three independent experiments in each study are showof those inflammatory mediators. Compound c26 performs
its anti-inflammatory activity through the ERK pathway
in vitro. In vivo, we detected the phosphorylation of
MAPKs in lung tissue with ALI. Data from Figure 8E
shows that curcumin and c26 reduced the LPS instillation






















ages were cultured with or without c26 for 30 min and stimulated
nd the total protein was extracted. The protein level of p-ERK, ERK,
Compound c26 dose-dependently decreased ERK phosphorylation.


























































































Figure 6 Compound c26 attenuated lung pathophysiologic changes in LPS-challenged rats. Effects of c26 on the total protein concentration
in (A) BALF and (B) the lung W/D ratio of LPS-induced ALI in rats. Statistical significance relative to LPS group was indicated, *p < 0.05. (C) Compound


































































































































CON LPS CUR+LPS c26+LPS
D EA B
C
Figure 7 Compound c26 attenuated lung inflammation in LPS-treated rats. Compound c26 reduced LPS-induced number of (A) neutrophils
and (B) monocytes in BALF, (C) Compound c26 reduced LPS-induced macrophages infiltration in lung tissue (CD68 immunostaining). Effect
of c26 inhibited the inflammatory cytokine TNF-α expression in (D) serum and (E) BALF. Statistical significance relative to LPS group was
indicated, *p < 0.05, **p < 0.01.


























































































































CON LPS CUR+LPS c26+LPS
E
Figure 8 Effects of c26 inhibited the LPS-induced inflammatory gene expression and inflammatory pathway in lung tissue. (A) TNF-α,
(B) IL-6, (C) IL-1β, and (D) COX-2 mRNA expression. (E) The phosphorylation of MAPKs. Statistical significance relative to LPS group was
indicated, *p < 0.05, **p < 0.01.
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coincided with the data in vitro. These results indicate ad-
ministration of c26 in vivo efficiently attenuated pulmon-
ary inflammation in LPS-induced ALI by inhibiting the
phosphorylation of ERK.
Inhibition of IL-6 and IL-1β mRNA expression in human
pulmonary epithelial cells
We further examined the inhibitory effects of c26 on
LPS-stimulated mRNA expressions of TNF-α, IL-6, IL-1β
and COX-2 in human pulmonary epithelial Beas-2B cells.
Figure 9 shows that mRNA levels of pro-inflammatory
cytokines, IL6 and IL1β, significantly increased after LPS
stimulation for 12 h in Beas-2B cells. In contrast, pre-
treatment with c26 significantly suppressed the elevated
mRNA expressions of IL6 and IL1β. In addition, c26
attenuated the mRNA expressions of TNF-α and COX-2.
within comparison to c26, curcumin showed a weaker ef-
fect on the inflammatory genes expression. The results
observed in pulmonary epithelial cells in vitro are consist-
ent with that of in rats with ALI in vivo. Collectively, these
findings provide further evidence that lead compound c26could have a therapeutic effect on ALI by down-regulating
the expression of the pro-inflammatory cytokine genes.
Discussion
Acute lung injury (ALI) plays a pivotal role in the death
of patients in intensive care unit. There is considerable
experimental and clinical evidence indicates that inflam-
matory cytokines play a major role in the pathogenesis of
LPS-induced lung injury [4,30]. A variety of new medica-
tions have appeared for the treatment of acute lung injury
and new research on traditional therapies has been
performed [31]. However, numerous pharmacological
therapies for established ALI, including corticosteroids
and steroids, have failed to show any therapeutic benefit
in clinical trials [31,32].
TNF-α and IL-6 are important pro-inflammatory cyto-
kines that can stimulate production of a host of other
cytokines [33]. They have been measured to be elevated
in ARDS BALF, however, measured values do not predict
clinical outcome [34]. IL-6 gene-deficient mice are insensi-
tive to pneumococcal pneumonia following intranasal



























































































































Figure 9 Compound c26 reduced the LPS-induced inflammatory genes expression in human lung epithelial cells. (A) TNF-α, (B) IL-6, (C)
IL-1β, (D) COX-2. The results were presented as the percent of LPS control. Each bar represents mean ± SEM of three independent experiments.
Statistical significance relative to LPS group was indicated, *p < 0.05, *p < 0.01.
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to attenuate LPS-induced acute lung injury via down-
regulation of TNF-α and IL-6 production [36-38]. In
our study, the majority of the synthesized compounds
had the ability to reduce LPS-induced TNF-α and IL-6
production (Figure 2). Furthermore, the active compounds
a17, a18, c9 and c26 showed a dose-dependent inhibitory
activity (Figure 3). These results demonstrated that the
synthesized compounds have the potential to treat ALI by
inhibiting inflammatory cytokines production.
After LPS incubation, TLR4 signaling was initiated, thus
leading to the activation of NF-kB and MAPK [39]. NF-κB
is a nuclear transcription factors that controls tran-
scription of DNA [40]. Many researchers have reported
that curcumin and curcumin analogs have the ability to
inhibit the LPS-induced activation of NF-κB [21,41]. Un-
fortunately, the compounds in our research exhibited
no effect on the activation of NF-κB (Data not shown).
MAPK are a family of protein serine/threonine kinases
that contain three subunits which include ERK, JNK,
and P38 MAPK [42]. Increased activity of MAPK and
their involvement in the regulation of the synthesis of
inflammatory mediators at the level of transcription
and translation, make them potential targets for anti-
inflammatory therapeutics [43,44]. Zhan et al. reportedthat penehyclidine hydrochloride ameliorated acute lung
injury through the inhibition of ERK1/2 and p38 MAPK
activation in septic mice [45]. In this study, we found
that LPS could activate all of three pathways of MAPKs
(Figure 3A). Interestingly, compound c26 exhibited no
inhibitory ability on the phosphorylation of JNK and p38,
however, it dose-dependently inhibited ERK phosphoryl-
ation induced by LPS (Figure 5). These results suggest
that the inhibition of the production of TNF-α and IL-6
by c26 may be mediated by the down-regulation of
the ERK signaling. The underlying mechanism of the
anti-inflammatory action of c26 needs to be further
investigated.
It has been reported that sepsis, especially gram nega-
tive bacteria infection, is the main cause of ALI/ARDS
[46,47]. LPS, a major component of gram negative bac-
teria cell walls, was usually used to induce ALI in animals
[48,49]. In our in vivo study, the model of acute lung
injury was induced by intratracheal instillation LPS. LPS
significantly increased protein concentration and the
number of inflammatory cells in BALF, pulmonary edema,
pulmonary histopathological changes, inflammatory cyto-
kines in serum and BALF, macrophages infiltration, in-
flammatory cytokine mRNA levels and inflammatory
pathway (Figures 6, 7 and 8). However, pretreatment with
Zhang et al. Respiratory Research  (2015) 16:43 Page 12 of 13c26 attenuated the increase of these markers induced
by LPS through inhibited the phosphorylation of ERK.
In summary, the most active compound, c26, exhibited
its anti-inflammatory activity in vitro and attenuated
LPS-induced acute lung injury by reducing inflamma-
tory responses in vivo through ERK pathway. This art-
icle provides a potential compound for the treatment
of acute lung injury.Conclusions
In conclusion, we designed and synthesized 30 curcumin
analogs based on the structure of curcumin and C66. In
vitro, most curcumin analogs showed better activity on
LPS-induced production of TNF-α and IL-6 than C66.
Active compounds, a17, a18, c9, and c26, exhibited their
anti-inflammatory activity in a dose-dependent manner
and showed high chemical stability in vitro. From the
perspective mechanisms, compound c26 dose-dependently
inhibited LPS-induced ERK phosphorylation in macro-
phages. In rat models with ALI, pretreatment with c26
significantly attenuated LPS-induced pulmonary edema,
pathological changes, inflammatory cytokines in serum
and BALF, inflammatory cell infiltration, inflammatory
cytokine mRNA expression and ERK phosphorylation.
This presents the possibility that curcumin analogs might
serve as potential agents for the treatment of ALI. Al-
though the anti-inflammatory mechanism and underlying
targets are still unknown, the beneficial effects of these
compounds on LPS-induced inflammation make c26 one
of important leads in the continuing drug development
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